Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 26, Issue 2, 2009, Pages 132-138

  Corte, T J ^a,b   Ellis, R ^a   Renzoni, E A ^a,c   Hansell, D M ^a,c   Nicholson, A G ^a,c   Du Bois, R M ^a,c   Wells, A U ^a,c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Connective tissue disease; Idiopathic interstitial pneumonia; Interstitial lung disease; Intravenous cyclophosphamide; Non specific interstitial pneumonia; Organizing pneumonia

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; CONSENSUS; DEATH; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; THORAX RADIOGRAPHY; VOMITING;

BIOPSY; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 77649244634     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis and rheumatism 2006; 54 (12): 3962-70.
2. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29 (2): 298-304.
3. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29 (4): 731-6.
4. Nanki N, Fujita J, Yamaji Y, et al. Nonspecific interstitial pneumonia/ fibrosis completely recovered by adding cyclophosphamide to corticosteroids. Intern Med 2002; 41 (10): 867-70.
5. Okada M, Suzuki K, Matsumoto M, et al. Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases. Mod Rheumatol 2007; 17 (2): 131-6.
6. Purcell IF, Bourke SJ, Marshall SM. Cyclophosphamide in severe steroid-resistant bronchiolitis obliterans organizing pneumonia. Respir Med 1997; 91 (3): 175-7.
7. Contreras G, Tozman E, Nahar N, Metz D. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 2005; 14 Suppl 1: s33-8.
8. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350 (10): 971-80.
9. Boumpas DT, Austin HA, 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340 (8822): 741-5.
10. Austin HA, 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314 (10): 614-9.
11. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40 (12): 2187-98.
12. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41 (10): 1835-44.
13. Haubitz M, Frei U, Rother U, Brunkhorst R, Koch KM. Cyclophosphamide pulse therapy in Wegener's granulomatosis. Nephrol Dial Transplant 1991; 6(8): 531-5.
14. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354 (25): 2655-66.
15. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford) 2007; 46(1): 124-30.
16. Yoshida T, Koga H, Saitoh F, et al. Pulse intravenous cyclophosphamide treatment for steroid-resistant interstitial pneumonitis associated with polymyositis. Intern Med 1999; 38 (9): 733-8.
17. Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Alimentary pharmacology & therapeutics 2002; 16 (10): 1751-9.
18. Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 2005; 22 (9): 775-82.
19. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89 (4): 403-10.
20. Zisman DA, Lynch JP, 3rd,Toews GB, Kazerooni EA, Flint A, Martinez FJ. Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest 2000; 117 (6): 1619-26.
21. Martinez FJ, McCune WJ. Cyclophosphamide for scleroderma lung disease. N Engl J Med 2006; 354 (25): 2707-9.
22. McCarthy CJ, Sheldon S, Ross CW, McCune WJ. Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. Arthritis Rheum 1998; 41 (8): 1493-6.
23. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003; 58 (2): 143-8.
24. Vogelmeier C. IPF or NSIP? That is the question. Eur Respir J 2003; 22 (2): 191-2.
25. Nagai S, Kitaichi M, Itoh H, Nishimura K, Izumi T, Colby TV. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12 (5): 1010-9.
26. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. American journal of respiratory and critical care medicine 2003; 168 (5): 531-7.
27. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18 (6): 455-61.
28. Houssiau F. Thirty years of cyclophosphamide: assessing the evidence. Lupus 2007; 16 (3): 212-6.